Skip to main content

RSV clinical trials at UCLA

3 in progress, 1 open to eligible people

Showing trials for
  • EDP 938 Regimens in Children With RSV

    open to eligible people ages up to 36 months

    A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.

    Los Angeles, California and other locations

  • Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

    Sorry, in progress, not accepting new patients

    The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to <60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).

    Los Angeles, California and other locations

  • Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

    Sorry, in progress, not accepting new patients

    The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to <24 months.

    Los Angeles, California and other locations

Our lead scientists for RSV research studies include .

Last updated: